The company specializes in oncological immunotherapy products such as OnkoBCG 50 and 100 for treating superficial and non-invasive bladder tumors, as well as immunoglobulin and vaccine products. Synthaverse manufactures one of the few drugs used internationally in the oncological immunotherapy of bladder cancer.
Cyborg Score Rationale
Synthaverse operates in a specialized pharmaceutical niche with established products and international reach, but demonstrates financial challenges with recent quarterly losses and modest market capitalization. The company's historic immunotherapy expertise provides competitive advantage, though recent profitability concerns and valuation metrics suggest mixed investment quality.
Top Insights
Rebranded from BIOMED-LUBLIN to Synthaverse in July 2023 to reflect development strategy and modernization efforts
Recent financial performance shows net losses: -7.72M PLN (Q3 2025) and -4.77M PLN (Q2 2025), indicating profitability challenges
Specializes in rare immunotherapy oncology products with limited global competition, providing competitive moat
Low market capitalization (~$79.8M as of Feb 2026) relative to revenue base ($13.9M TTM) suggests high-risk micro-cap positioning
Named Competitors
BCG Immunotherapy Products — Large pharma companies with broader oncology portfolios
Immunoglobulin Products — Global plasma-derived products manufacturers
Recent Developments
(Feb 2026) Stock trading at $1.05 with 75.8M shares outstanding
(Sep 2025) Trailing 12-month revenue of $13.9M reported
(Jul 2023) Completed rebranding from BIOMED-LUBLIN S.A. to Synthaverse S.A.
Open the full interactive Synthaverse S.A. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.